🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 18 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 19/10/2001 | 21,76 | 23,34 | 21,74 | 22,85 | +1,78% | 7,35% | 734.000 |
| 18/10/2001 | 22,20 | 22,85 | 22,14 | 22,45 | +1,13% | 3,20% | 732.900 |
| 17/10/2001 | 24,85 | 24,85 | 22,19 | 22,20 | -7,04% | 10,70% | 1.379.200 |
| 16/10/2001 | 21,90 | 24,23 | 21,90 | 23,88 | +10,86% | 10,64% | 2.157.100 |
| 15/10/2001 | 20,10 | 21,73 | 20,10 | 21,54 | +3,91% | 8,11% | 939.300 |
| 12/10/2001 | 20,17 | 21,03 | 19,76 | 20,73 | +0,44% | 6,30% | 493.500 |
| 11/10/2001 | 20,20 | 21,61 | 20,14 | 20,64 | +3,72% | 7,28% | 1.216.400 |
| 10/10/2001 | 17,98 | 19,91 | 17,95 | 19,90 | +10,74% | 10,90% | 468.600 |
| 09/10/2001 | 18,30 | 18,95 | 17,86 | 17,97 | -1,05% | 5,96% | 327.400 |
| 08/10/2001 | 18,70 | 19,19 | 17,85 | 18,16 | -4,97% | 7,17% | 352.700 |
| 05/10/2001 | 19,40 | 19,53 | 17,91 | 19,11 | +0,95% | 8,35% | 520.400 |
| 04/10/2001 | 19,28 | 20,57 | 18,50 | 18,93 | +0,16% | 10,74% | 1.357.400 |
| 03/10/2001 | 18,01 | 19,94 | 17,55 | 18,90 | +4,83% | 13,27% | 1.385.200 |
| 02/10/2001 | 17,00 | 18,25 | 16,74 | 18,03 | +5,75% | 8,88% | 815.500 |
| 01/10/2001 | 17,86 | 18,34 | 16,93 | 17,05 | -5,49% | 7,89% | 986.700 |
| 28/09/2001 | 17,85 | 19,03 | 17,59 | 18,04 | +4,88% | 8,07% | 1.526.000 |
| 27/09/2001 | 15,55 | 17,56 | 15,50 | 17,20 | +4,37% | 13,25% | 2.452.200 |
| 26/09/2001 | 17,50 | 17,65 | 15,92 | 16,48 | -4,41% | 9,89% | 2.286.100 |
| 25/09/2001 | 17,61 | 18,05 | 17,00 | 17,24 | -2,82% | 5,96% | 4.213.000 |
| 24/09/2001 | 21,41 | 21,41 | 16,09 | 17,74 | -24,41% | 24,85% | 9.844.500 |
| 21/09/2001 | 23,79 | 25,10 | 21,20 | 23,47 | -9,73% | 16,39% | 1.367.300 |
| 20/09/2001 | 25,40 | 26,75 | 24,07 | 26,00 | -2,07% | 10,55% | 978.700 |
| 19/09/2001 | 25,36 | 26,99 | 23,56 | 26,55 | +3,51% | 13,53% | 1.548.400 |
| 18/09/2001 | 28,81 | 29,40 | 25,30 | 25,65 | -10,31% | 14,23% | 1.133.600 |
| 17/09/2001 | 28,95 | 30,25 | 27,45 | 28,60 | -7,35% | 9,67% | 1.879.800 |
| 10/09/2001 | 32,11 | 32,73 | 30,16 | 30,87 | -4,99% | 8,00% | 1.614.400 |
| 07/09/2001 | 33,88 | 34,19 | 32,36 | 32,49 | -4,97% | 5,40% | 1.043.300 |
| 06/09/2001 | 36,15 | 36,21 | 33,99 | 34,19 | -5,50% | 6,14% | 598.700 |
| 05/09/2001 | 37,25 | 37,58 | 35,60 | 36,18 | -2,58% | 5,32% | 618.500 |
| 04/09/2001 | 37,20 | 38,60 | 36,77 | 37,14 | +0,68% | 4,92% | 498.500 |